Drugmakers Aim to Curb Release of Antibiotic Waste Into the Environment

  A coalition of drugmakers is introducing new standards aimed at curbing the release of antibiotic waste into the environment amid growing concerns over drug resistance that’s been linked to more than a million annual deaths globally.   The guidelines will help ensure antibiotics are made responsibly, minimizing environmental risks, the AMR Industry Alliance said […]

Antibiotic Drugmakers Take Steps to Self-Impose Environmental Safeguards

LONDON, June 14 (Reuters) – In the absence of global standards limiting toxic emissions produced by antibiotics at the point of manufacture, the pharmaceutical industry has come up with its own standard. The AMR Industry Alliance – a coalition of drugmakers, biotech, diagnostic and other companies involved in the field of antimicrobials – said on […]

Health Europa Quarterly Issue 21 Explores AMR

Health Europa Quarterly has published its twenty-first issue which features AMR, as well as the AMR Industry Alliance’s Progress Report, acknowledging “the urgent need to facilitate a sustainable market for new antibiotics,” and that “the global AMR crisis can only be tackled through high level, cohesive action.” From the article, “Progress being made on AMR, […]

AMR Progress Report in Health Europa Quarterly

AMR Industry Alliance and its Progress Report have been featured in Health Europa Quarterly: Progress being made on AMR, but marketplace reforms needed   “AMR Industry Alliance discusses the findings from their latest progress report, which pays heed to the importance of a global, multi-stakeholder approach to tackle AMR. Antimicrobial resistance – the evolution of […]

Manufacturers of new antibiotics go bankrupt

700,000 people die from drug-resistant infections – so why do antibiotic companies face bankruptcy? This article was first published in the NZZamSonntag on 26 January 2020 by Birgit Voigt

Industry urges more government action on antibiotic development

This article was published in CIDRAP 16 January 2020. A report by Chris Dall. The level of funding for late-stage research and development of new antibiotics and other products to combat antimicrobial resistance (AMR) is insufficient to meet global health needs, and governments need to step up to the plate, according to an industry report released […]